Climb Bio, Inc. (CLYM)

Pharmaceutical Preparations · market cap $746M · as of 2026-07-22

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-11-05 (est.)

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Climb Bio, Inc. (CLYM) is a pharmaceutical company with a single disclosed pipeline asset, budoprutug, currently in Phase 2 development for Primary Membranous Nephropathy (PMN). With a ~$700M market cap, only $8.4M in cash, and a stated runway of approximately 1.7 months, the company faces an acute near-term financing crisis that dominates the risk profile regardless of clinical merit.

The catalyst path

2026-11-05 (est.)Earningsimp 5/10

Pipeline

Asset	Phase	Indication
budoprutug	Phase 2	Primary Membranous Nephropathy

Price & technical context

3-month

-14.2%

6-month

+59.3%

12-month

+450.7%

52-wk range

$1.64–$17.84

vs 50-day MA

-21.5%

vs 200-day MA

+13.6%

Realized vol

93.7%

Max drawdown

-86.6%

Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for CLYM (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.